glp-1 receptor agonist and dpp-4 inhibitor combination not recommended analogues inhibitors in type 2 diabetes therapy: from structural biology to clinics Differences between GLP-1 receptor agonists

Behavioral phenotyping and pathological indicators of Parkinsons disease in C

From looking at the reported data in the paper, BPC-157 worked no better than the high dose platelet-rich plasma (PRP) that our lab research group tested in another study (3)

The COVID-19 global pandemic, or any future public health crisis, and the ensuing policies enacted by governments and central banks have caused and may continue to cause significant volatility and uncertainty in global financial markets, negatively impacting global growth prospects

A deficiency in NAD+, or a disruption in NAD+ homeostasis in the body, may impair these physiologic processes, which may result in different illnesses or disease conditions

Davis RJ